ASH 2020 | Cilta-cel achieves deep and durable responses for R/R multiple myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an update on the ongoing Phase Ib/II CARTITUDE-1 study (NCT03548207) investigating ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-targeting therapy for patients with relapsed/refractory (R/R) multiple myeloma. Combined results from the Ib and II portions of the study have found an overall response rate (ORR) of over 95% and a median progression-free survival (PFS) of 75% at 12.4 months. Dr Martin also discusses how patients have a significant improvement in quality of life. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding to institution: Sanofi, Janssen, AMGEN
Consultancy: GSK
